Clinical trial

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

NCT00038246

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Estramustine Normalized identity: estramustineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Thalidomide Normalized identity: thalidomideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Paclitaxel (Taxol) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2000-10-01

PhasePHASE1 / PHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

EstramustineDRUG · verified · RxNorm: estramustine

ThalidomideDRUG · verified · RxNorm: thalidomide

Paclitaxel (Taxol)DRUG

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

Celgenecollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00038246 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.